On January 31, 1979, the Olin Corporation ('Olin') submitted a report to your offices through our Counsel, our concerns regarding the number of incidences of myocardial infarcts in a definitive group of employees working in the Olin hydrazine production facility at Lake Charles Louisiana. We agreed, at that time, to do a further long-term in-depth epidemiology study of these people associated with this facility. That study has been completed and is summarized in the attached report from our consultant epidemiologist, Peter Hamill, M.D. His report in turn has been reviewed by a second epidemiologist, Wistar Meigs, M.D. of Yale University. The conclusions, which have been reached as a result of this investigation, are (1) since 1977, there have not been any known cases of myocardial infarcts in any of the hydrazine workers; and (2) the experienced cluster of incidents was a chance occurrence and does not therefore, represent a direct health hazard related myocardial involvement. To the best of our knowledge, there has been no changes in the operations, the levels of exposure, nor in the character of operating personnel. A careful review of all available literature summarized in a 1974 report of the National Research Council, Advisory Center on Toxicology, on the subject of Hydrazine does not project any myocardial disease implicative from exposure to the vapors of any of the other forms of hydrazine (monomethyl, and 1,I, dimethyl) as well as the anhydrous. Therefore, it is our conclusion that evidence supporting the claim that hydrazine may cause myocardial infarct is lacking and is not factual. However, through our Medical Department, we shall continue to be alerted to any future abnormalities which may be associated with this subject.